



## **Innovate Biopharmaceuticals, Inc. will be Attending the 2016 Piper Jaffray Healthcare Conference Meeting in San Diego from Friday, May 20 - 23, 2016**

May 18, 2016

RALEIGH, N.C., May. 18, 2016 -- [Innovate Biopharmaceuticals](#) Inc., a clinical stage biotechnology company focused on autoimmune/inflammation diseases with Larazotide acetate entering Phase 3 trials and INN-108 entering Phase 2 next year will be at the 2016 Digestive Disease Week conference.

Contact us via email to schedule meetings during [DDW](#): [investor.relations@innovatebiopharma.com](mailto:investor.relations@innovatebiopharma.com).

### **About Innovate Biopharmaceuticals, Inc.**

Innovate is a privately held, clinical stage biotechnology company focused on developing novel autoimmune/inflammation medicines. Innovate's lead drug candidate, Larazotide acetate (INN-202), is a novel oral peptide that has consistently shown to reduce clinical symptoms of celiac disease in multiple clinical trials testing more than 800 patients. Larazotide has completed a large phase 2b study and will start Phase 3 trials in 2017. Larazotide's unique mechanism of action of reducing antigen trafficking across epithelial cells makes it a promising therapeutic for multiple diseases involving "leaky tight junctions."

Innovate's second therapeutic in clinical development, INN-108, is an oral small molecule entering Phase 2 trials for the treatment of adult orphan indication as well as mild to moderate ulcerative colitis. INN-108 is a prodrug that only becomes activated in the colon and the convenience of a liquid formulation will be important to children and the aging.

### **Forward Looking Statements**

This release contains forward-looking statements, including statements regarding the clinical development of our product candidates which are subject to risks and uncertainties that could cause actual results to differ materially. Reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongst others. These forward-looking statements speak only as of the date hereof. Innovate Biopharmaceuticals disclaims any obligation to update these forward-looking statements.

### **Investor Relations**

Kendyle Woodard  
Tel: +1 (919) 275 - 1933  
[investor.relations@innovatebiopharma.com](mailto:investor.relations@innovatebiopharma.com)  
[www.innovatebiopharma.com](http://www.innovatebiopharma.com)